Principal investigator for cell therapy team – Hematooncology and Immunotherapy
The Department of Hematooncology of the Faculty of Medicine, University of Ostrava announces the selection procedure:
Principal investigator for cell therapy team – Hematooncology and Immunotherapy
5 years duration, full-time, (NOTE: Possibility to extend the stay depending on additional successful funding)
University/Department:
- Faculty of Medicine, University of Ostrava, Department of Hematooncology
Location:
- 17. listopadu 1790/5 708 52 Ostrava-Poruba, Czech Republic
Research field:
- Hematooncology and Immunotherapy
Our research:
- The Blood Cancer Research Group is a recently established young international team led by experienced scientists with many national and international collaborations and outstanding publication tracks. It provides an attractive opportunity to pursue a career in science. Our research projects focus on molecular mechanisms of cancer resistance to therapy and novel approaches to treat hematologic malignancies harnessing the immune system's natural antitumor capacity. Our research center benefits from a large biobank with access to unique patient samples and a modern animal center. We employ the latest experimental approaches, including next-generation sequencing, CRISPR-Cas9 genome modification, mass spectrometry, non-invasive bioluminescence imaging in tumor mouse models, and various molecular, biochemical, and cell biology techniques. Besides, we have collaborations with prestigious international medical centers, pharma and biotech companies, resulting in several patent applications. Our goal is to transfer research findings to the stage of clinical trials. The details of the projects are available upon request.
Job description:
- The University of Ostrava invites applications for becoming the principal investigator (PI) in the cell-based cancer immunotherapy team within the Blood Cancer Research Group. They will be responsible for planning and performing biological experiments, analyzing results, presenting results at regular meetings, workshops, and conferences, supervising young scientists and technicians working on the project, and writing scientific publications. Moreover, the PI will participate in a recently established cell therapy-focused start-up company and newly planned manufacturing facility. We are looking for a highly motivated, enthusiastic, proactive scientist with well-documented experience and a deep interest in biomedical research. Background in Molecular biology, Cell Biology, Immunology, Animal handling, Microbiology, or Biochemistry is desired. Good command of the English language, including writing skills, is mandatory.
Benefits
Salary:
- We offer competitive salary over 3 000 EUR/month (gross), commensurate with experience
We also offer:
- 5 sick days;
- 30 days off;
- meal vouchers;
- TEP – sport activities.
Selection process
Important Dates:
- Application deadline: 5th March 2022
Formal requirements
The candidate will send the following documents.
- Curriculum vitae in English (incl. description of international experiences)
- Brief motivation letter with two references
- List of publications
- Copy of the doctoral diploma
- Consent to data processing
The evaluation committee will carry out the first round of the selection process by assessing the submitted documents. The applications will be evaluated continuously until 5th March 2022.
The successful candidates will be invited to the second round of the selection (in English, in person, or online). The employer is entitled to cancel the tender without giving any reasons or not to select any candidates.
Contact:
e-mail: info.bcrg@fno.cz
Blood Cancer Research Group: www.bcrg.cz
University of Ostrava: http://www.osu.eu
Offer Requirements
- REQUIRED LANGUAGES
ENGLISH: Proficient
Skills/Qualifications
Eligibility and Selection Criteria
- At least 3 years since defending Ph.D. in immunology, molecular/cell biology, cancer biology, or related fields
- The researcher has been working for at least 2 years outside the Czech Republic during the last three years
- At least 2 publications in the last three years
10.2.2022